What are you researching?

The GLP-1 agonist that rewrote obesity medicine, and research has already moved past metabolism into neuroprotection, cardiovascular outcomes, even addiction. The evidence base is unusually deep for a peptide, anchored by large human trials under Ozempic and Wegovy. The wrinkle researchers flag is the gulf between that regulated product and "research-grade" gray-market material.

Mechanism

GLP-1 receptor agonist

Evidence base

Extensive

Research-use status

Approved drug · research framing

Surprised the field: adding GIP agonism to GLP-1 beat GLP-1-only drugs on weight loss, reopening a long argument over whether activating GIP should even help. That "twincretin" mechanism is why it's treated as a step-change rather than an increment. Human evidence is substantial — but research-grade material is a different thing from the approved drug (Mounjaro, Zepbound).

Mechanism

Dual GIP / GLP-1 receptor agonist

Evidence base

Extensive

Research-use status

Approved drug · research framing

A clever idea: isolate the fat-burning tail of growth hormone (residues 176-191) without the glucose and IGF-1 effects of the full hormone. The honest part is that human obesity trials underwhelmed, failing to clearly beat placebo — yet it persists in metabolic and anti-aging research. A strong mechanistic rationale meeting disappointing clinical data.

Mechanism

HGH(176-191) fragment; lipolysis

Evidence base

Emerging

Research-use status

Research-use only

This is where "with or without DAC" matters: the Drug Affinity Complex version binds albumin and stretches its half-life from minutes to days, changing how growth hormone is released. It's usually studied alongside a GHRP like ipamorelin — a steady GHRH signal paired with sharp GH pulses. A research compound, not an approved drug.

Mechanism

Long-acting GHRH analog

Evidence base

Moderate

Research-use status

Research-use only

Earned its reputation by being selective: it nudges growth hormone while largely leaving cortisol, prolactin, and hunger alone, unlike blunter secretagogues like GHRP-6. That "clean" profile is exactly why it's the go-to ghrelin-mimetic in GH-axis research. Research-use-only, studied mostly in recovery and metabolic models.

Mechanism

Selective GH secretagogue

Evidence base

Moderate

Research-use status

Research-use only

The outlier with real regulatory standing: an FDA-approved GHRH analog, originally for HIV-associated visceral fat. What interests researchers is that it genuinely reduced deep abdominal fat in controlled human trials — a harder endpoint than most peptides can show. Research-grade material is still distinct from the approved drug (Egrifta).

Mechanism

GHRH analog; visceral-fat research

Evidence base

Moderate

Research-use status

Approved drug · research framing

The longevity field's most tantalizing and most disputed peptide: a synthetic version of a pineal-gland peptide that the original Russian researchers tied to telomerase activation and even lifespan extension. The intrigue is real; so is the caveat that much of the striking data traces to a single research lineage and has been hard to reproduce. Strictly a research compound.

Mechanism

Tetrapeptide; telomerase / pineal research

Evidence base

Emerging

Research-use status

Research-use only

One of the few peptides here your own body makes, and loses: plasma levels fall ~60% between your twenties and sixties. That decline is what drew researchers in — gene-expression studies suggest the copper-bound tripeptide can shift a large set of genes back toward a younger profile. Its double life as both a longevity tool and a serious cosmetic-science ingredient is what makes it unusual.

Mechanism

Copper tripeptide; tissue remodeling

Evidence base

Moderate

Research-use status

Research-use only

The outlier with real regulatory standing: an FDA-approved GHRH analog, originally for HIV-associated visceral fat. What interests researchers is that it genuinely reduced deep abdominal fat in controlled human trials — a harder endpoint than most peptides can show. Research-grade material is still distinct from the approved drug (Egrifta).

Mechanism

GHRH analog; visceral-fat research

Evidence base

Moderate

Research-use status

Approved drug · research framing

A reminder that the evidence map isn't the same everywhere: it's an actually-prescribed nootropic in Russia, derived from an ACTH fragment, yet nearly unknown to Western clinical practice. Mechanistically it's studied for upregulating BDNF, the growth factor tied to neuroplasticity and recovery. That East-West gap is what keeps it a recurring research subject.

Mechanism

ACTH(4-10) analog; neurotrophic

Evidence base

Emerging

Research-use status

Research-use only

Built to answer one question: can you get anxiolytic effects without the sedation and dependence of benzodiazepines? Derived from the immune peptide tuftsin, it's studied for modulating GABA and serotonin while also touching immune pathways — an unusual dual character. A research compound, developed and trialed largely in Russia.

Mechanism

Tuftsin analog; anxiolytic

Evidence base

Emerging

Research-use status

Research-use only

Far more than the labor hormone it's clinically known for; it became one of neuroscience's most-studied molecules for bonding, trust, and autism research. It also carries a cautionary tale: a wave of headline intranasal-oxytocin findings that later struggled to replicate — now part of any serious discussion of it. Research-grade oxytocin is distinct from its pharmaceutical form (Pitocin).

Mechanism

Nonapeptide hormone

Evidence base

Extensive

Research-use status

Approved drug · research framing

Not thymosin β4, but a synthetic fragment of it — which is exactly the debate: whether a short active region reproduces the full protein's repair signaling. What's consistent is its effect on actin regulation and angiogenesis, making it a frequent partner to BPC-157 in tissue-repair models. Human data is thin; it's WADA-prohibited.

Mechanism

Thymosin β4 fragment; actin regulation & repair

Evidence base

Moderate

Research-use status

Research-use only

The compound that pulled peptide research into the mainstream: a 15-amino-acid fragment stable enough to survive stomach acid, which is rare and part of why it's studied across so many tissue types. Animal work points to fast tendon, ligament, and gut repair — but the honest caveat is that almost none of it has replicated in humans, and it's WADA-banned. The textbook case of popularity outrunning clinical evidence.

Mechanism

Pentadecapeptide; cytoprotection & angiogenesis

Evidence base

Extensive

Research-use status

Research-use only

One of the few peptides here your own body makes, and loses: plasma levels fall ~60% between your twenties and sixties. That decline is what drew researchers in — gene-expression studies suggest the copper-bound tripeptide can shift a large set of genes back toward a younger profile. Its double life as both a longevity tool and a serious cosmetic-science ingredient is what makes it unusual.

Mechanism

Copper tripeptide; tissue remodeling

Evidence base

Moderate

Research-use status

Research-use only